CRSP Forex-Nachrichten
Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology
Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).
RTTNews
|
vor 661 Tagen
CRISPR Therapeutics Says FDA Grants RMAT Designation To CTX130
Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).
RTTNews
|
vor 841 Tagen
